China’s New Essential Drug List Adds Drugs For Major Diseases, But Pricing, Market Pressure Likely To Increase
This article was originally published in The Pink Sheet Daily
Executive Summary
China adds 14 new oncology drugs to its newly revised Essential Drug List, as well as human insulins and hemophilia agents for the first time. Notable MNC drugs include Pfizer’s Norvasc, Novartis’ Diovan, Sanofi’s blood thinner Plavix and Bayer’s Glucobay.